Hints and tips:
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Viatris, in response to questions, said the drug was “complex” and “involves an exceptionally long cycle time to produce”....
...That might justify a steeper EV-to-forward ebitda multiple than the seven times commanded by quoted generics companies Teva and Viatris. The unit might fetch at least $15bn, according to Bernstein....
...BIG BIOTECH DEALS OF 2005 ($m) Novartis Chiron 5,100 Pfizer Vicuron 1,900 Shire Transkaryotic Therapies 1,600 GSK ID Biomedical 1,400 AstraZeneca AtheroGenics 1,000 OSI EyeTech 935 Meda Viatris 927...
International Edition